Protalix BioTherapeutics (PLX) Net Income Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 60.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 19.97% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 47.10% |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 98.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.94% |
| Dec 31, 2025 | -10.34% |
| Sep 30, 2025 | 38.85% |
| Jun 30, 2025 | 27.53% |
| Mar 31, 2025 | -16.55% |
| Dec 31, 2024 | 53.74% |
| Sep 30, 2024 | 40.16% |
| Jun 30, 2024 | 42.13% |
| Mar 31, 2024 | 7.79% |
| Dec 31, 2023 | -330.66% |
| Sep 30, 2023 | 25.92% |
| Jun 30, 2023 | 80.39% |
| Mar 31, 2023 | -60.55% |
| Dec 31, 2022 | -213.86% |
| Sep 30, 2022 | 0.25% |
| Jun 30, 2022 | 11.69% |
| Mar 31, 2022 | 32.56% |
| Dec 31, 2021 | -6.13% |
| Sep 30, 2021 | 8.20% |
| Jun 30, 2021 | -10.02% |
| Mar 31, 2021 | 7.36% |
| Dec 31, 2020 | 26.63% |
| Jun 30, 2019 | -304.54% |
| Mar 31, 2019 | -369.55% |
| Dec 31, 2018 | -27.40% |
| Sep 30, 2018 | -65.45% |
| Jun 30, 2018 | -113.10% |
| Mar 31, 2018 | -150.00% |
| Jun 30, 2016 | 74.30% |
| Mar 31, 2016 | 74.69% |
| Dec 31, 2015 | 115.54% |
| Sep 30, 2015 | 33.79% |
| Jun 30, 2015 | -51.29% |
| Mar 31, 2015 | 27.84% |
| Mar 31, 2014 | -13.59% |
| Dec 31, 2013 | -24.55% |
| Sep 30, 2013 | -25.61% |
| Jun 30, 2013 | 12.10% |